title: [A case of malignant meningioma treated by individual adjuvant chemotherapy based on the mRNA expression of drug-resistance gene].
abstract: We report a case with malignant meningioma in which new preliminary treatment trial was performed by chemotherapy using anti-cancer drugs selected on the basis of multidrug resistance gene mRNA expression, such as MDR1, MGMT, MRP1, MRP2, MXR1, and DNA topoisomerase II alpha, from RT-PCR assay. A 43-year-old female had been operated for parasagittal anaplastic meningioma three times because of recurrences. partial removal of tumor was performed at the 3rd operation. RT-PCR assay of this tissue revealed overexpression of MDR1, MRP1, MRP2 and MGMT mRNA, but no ABCG 2 expression was observed. The patient was given mitoxantrone and hydroxyurea following irradiation, after which the tumor did not recur for three years. Preliminary individual adjuvant chemotherapy based on mRNA expression of drug-resistance gene is available for the treatment of recurrent malignant meningioma.
authors.affiliation: Dept. of Neurosurgery, Kawasaki Hospital.
authors.forename: Katsuzo
authors.initials: K
authors.lastname: Kunishio
authors.forename: Kazuki
authors.initials: K
authors.lastname: Kobayashi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kagawa
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Makabe
authors.forename: Akira
authors.initials: A
authors.lastname: Matsumoto
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Matsumoto
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000096:biosynthesis / Q000235:genetics; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D015254:DNA Modification Methylases; D045643:DNA Repair Enzymes; D004334:Drug Administration Schedule; D018432:Drug Resistance, Multiple / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D026901:Membrane Transport Proteins / Q000096:biosynthesis; D008577:Meningeal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000532:radiotherapy; D008579:Meningioma / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000532:radiotherapy; D008942:Mitoxantrone / Q000008:administration & dosage; D000089762:Multidrug Resistance-Associated Protein 2; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000096:biosynthesis; D012333:RNA, Messenger / Q000096:biosynthesis; D025803:Tumor Suppressor Protein p14ARF / Q000096:biosynthesis; D025521:Tumor Suppressor Proteins
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D015254:DNA Modification Methylases; D045643:DNA Repair Enzymes; D006918:Hydroxyurea; D026901:Membrane Transport Proteins; D008942:Mitoxantrone; D000089762:Multidrug Resistance-Associated Protein 2; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D012333:RNA, Messenger; D025803:Tumor Suppressor Protein p14ARF; D025521:Tumor Suppressor Proteins; C000715087:ABCC2 protein, human; C515491:MGMT protein, human